Soligenix Inc
SNGX
Market Cap$30.79M
Close$
$0.21
51.2% downside
Current Fair Value
51.2% downsideOvervalued by 51.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $30.79 Million |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $0.0 |
| Beta | 0.0 |
| Outstanding Shares | 10,524,437 |
| Avg 30 Day Volume | 237,849 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 0.0 |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
ESG Score
No data
About Soligenix Inc
18 employees
CEO: Christopher Schaber Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.